Johnson & Johnson (NYSE:JNJ) Shares Acquired by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 63,449 shares of the company's stock after buying an additional 3,101 shares during the period. GF Fund Management CO. LTD.'s holdings in Johnson & Johnson were worth $10,522,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. OneDigital Investment Advisors LLC increased its holdings in Johnson & Johnson by 1.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 87,424 shares of the company's stock worth $14,498,000 after acquiring an additional 916 shares during the last quarter. 44 Wealth Management LLC boosted its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. 44 Wealth Management LLC now owns 18,269 shares of the company's stock valued at $3,030,000 after acquiring an additional 260 shares during the last quarter. Avantax Planning Partners Inc. boosted its position in shares of Johnson & Johnson by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 44,955 shares of the company's stock valued at $7,455,000 after acquiring an additional 1,717 shares during the last quarter. Silver Oak Securities Incorporated boosted its position in shares of Johnson & Johnson by 13.8% during the 1st quarter. Silver Oak Securities Incorporated now owns 8,637 shares of the company's stock valued at $1,414,000 after acquiring an additional 1,045 shares during the last quarter. Finally, Calamos Wealth Management LLC boosted its position in shares of Johnson & Johnson by 15.3% during the 1st quarter. Calamos Wealth Management LLC now owns 116,394 shares of the company's stock valued at $19,303,000 after acquiring an additional 15,447 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JNJ. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.04 on Wednesday, hitting $155.75. The company's stock had a trading volume of 2,794,086 shares, compared to its average volume of 8,036,905. The company has a market capitalization of $374.75 billion, a price-to-earnings ratio of 17.32, a price-to-earnings-growth ratio of 2.35 and a beta of 0.41. The firm has a fifty day moving average price of $153.67 and a 200-day moving average price of $154.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.